BioCentury | Jul 18, 2020
Translation in Brief

Fate licenses rejection-resistant T cell therapies; plus a marker for anti-PD-1 treatment responsiveness, a cell proliferation control switch and more

Baylor’s engineered T cells designed to avoid immune rejection Baylor College of Medicine has granted Fate Therapeutics Inc. (NASDAQ:FATE) an exclusive license to alloimmune defense receptors, which render allogeneic cell therapies resistant to host immune...
BioCentury | Jul 16, 2020
Emerging Company Profile

Fountain Therapeutics: an AI-based platform to reverse cellular aging

Fountain is using an unbiased data-driven approach to identify compounds that reverse the biological process of aging, and in contrast to the traditional disease hypothesis-driven approach, the company is agnostic to indication. “Eighty percent of...
BioCentury | Mar 11, 2020
Product Development

COVID-19 patients on Ascletis’ HCV drug discharged; plus Mesoblast allogeneic stem cells for COVID-19, Acceleron, Bridge-Atomwise, Cellectis and Abpro

Eleven COVID-19 patients discharged after receiving Ascletis drug Ascletis Pharma Inc. (HKEX:1672) said all 11 COVID-19 patients in a cohort receiving Ganovo danoprevir plus ritonavir in a Chinese Phase IV trial have been discharged from...
BioCentury | Mar 11, 2020
Product Development

Novo’s year of obesity

Novo Nordisk is set to deliver six clinical readouts in obesity in 2020. If successful, they could deliver Novo an opportunity to dramatically expand a mostly untapped market that could become a major future growth...
BioCentury | Jan 28, 2020
Clinical News

Acceleron readout supports sotatercept as disease-modifying option for PAH

Acceleron is readying to send its pulmonary arterial hypertension candidate to Phase III after announcing late Monday that the therapy combined with standard of care met primary and secondary endpoints in a proof-of-concept Phase II...
BioCentury | Jan 15, 2020
Clinical News

Denali gains on Parkinson’s results as it looks to select a Phase II candidate

Denali reported data Tuesday from pair of Phase I trials that will inform the company’s selection of a Parkinson’s disease candidate to advance to Phase II. Denali Therapeutics Inc. (NASDAQ:DNLI) gained $5.16 (29%) to $22.74...
BioCentury | Dec 19, 2019

Skin grafts based on CRISPR-edited iPS cells to treat epidermolysis bullosa

DISEASE CATEGORY: Dermatology INDICATION: Blistering disorder Skin grafts based on CRISPR-edited induced pluripotent stem (iPS) cells could treat recessive dystrophic epidermolysis bullosa, a blistering disorder caused by mutations in COL7A1. Generation of the full-thickness grafts...
BioCentury | Dec 19, 2019

Promoting calcium channel signaling in muscle to treat age-related atrophy

DISEASE CATEGORY: Musculoskeletal INDICATION: Muscular atrophy Increasing signaling through the embryonic isoform of the skeletal muscle-specific calcium channel CACNB1 or its downstream effector GDF5 could treat age-related muscular atrophy. Transcript levels of both proteins were...
BioCentury | Nov 8, 2019
Clinical News

Roche’s RG6206 becomes second myostatin inhibitor to fail in DMD in past year

The failure of Roche’s RG6206 marks another blow to the hypothesis that blocking myostatin can improve muscle growth and function in ambulatory boys with Duchenne muscular dystrophy. Roche (SIX:ROG; OTCQX:RHHBY) sent a letter Wednesday to...
BioCentury | Oct 9, 2019
Company News

CTFH latest to partner with Insilico in AI discovery deal

In the latest addition to a growing roster of industry collaborations, AI company Insilico has partnered with CTFH to discover and develop two programs for triple-negative breast cancer. Insilico Medicine Inc. is eligible to receive...
Items per page:
1 - 10 of 295